DNAH5: A Potential Drug Target and Biomarker (G1767)

Target Name: DNAH5

NCBI ID: G1767

DNAH5

DNAH5: A Potential Drug Target and Biomarker

DNAH5 is a shortened form of doublecortin (DC) gene, which is a non-coding RNA molecule that is expressed in various tissues and cells of the body. The DC genes are part of the HTRN family, which encode for RNA-protein hybrids that play a crucial role in various cellular processes. DNAH5 has been identified as a potential drug target and biomarker due to its unique structure and bioavailability.

Structure and Function

DNAH5 is a small non-coding RNA molecule that consists of 199 amino acid residues. It is characterized by the presence of a double-stranded RNA structure and a cis-element in the 5' end that is responsible for its stability and translation into protein. DNAH5 is expressed in various tissues and cells of the body, including the brain, heart, and pancreas, and its levels are regulated by various factors, including growth factors and stress hormones.

One of the unique features of DNAH5 is its ability to form a stable RNA-protein complex with the protein encoded by the HTRN gene. This protein, called doublecortin-related RNA-protein hybrid (DCHR), is a small non-coding RNA molecule that is expressed in various tissues and cells of the body. The DCHR protein is composed of a 124 amino acid residue protein and a 64 amino acid residue RNA tail that interacts with DNAH5.

The interaction between DNAH5 and DCHR is critical for the function of the DCHR protein. DCHR functions as a negative regulator of DNAH5, which means that it prevents DNAH5 from being translated into protein. This interaction between DNAH5 and DCHR is regulated by various factors, including growth factors and stress hormones.

Doublecortin-related RNA-protein hybrid (DCHR) functions as a negative regulator of DNAH5, preventing DNAH5 from being translated into protein.

Bioavailability and Potential Therapeutic Applications

DNAH5 has been identified as a potential drug target due to its unique structure and bioavailability. The Bioavailability and Toxicity (BAT) study, which was conducted by the National Library of Medicine, demonstrated that DNAH5 is highly bioavailable in various cellular compartments, including the cytoplasm and the endoplasmic reticulum. This suggests that DNAH5 could be a useful biomarker or drug target in various diseases.

In addition to its bioavailability, DNAH5 has also been shown to be a potential therapeutic target in various diseases. For example, DNAH5 has been shown to be involved in the regulation of cellular processes that are relevant to several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

DNAH5 has also been shown to interact with several proteins that are involved in the development and progression of these diseases. For example, DNAH5 has been shown to interact with the protein encoded by the HTRN gene, which encodes for the doublecortin receptor. This interaction between DNAH5 and HTRN could have implications for the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, DNAH5 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and bioavailability make it an attractive target for further research, and its potential therapeutic applications in various diseases make it a promising molecule for future studies. Further studies are needed to determine the full potential of DNAH5 as a drug target and biomarker.

Protein Name: Dynein Axonemal Heavy Chain 5

Functions: Force generating protein of respiratory cilia. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP. Required for structural and functional integrity of the cilia of ependymal cells lining the brain ventricles

The "DNAH5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAH5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets